Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer

被引：41

作者：

Wu, Julie M.

Halushka, Marc K.

Argani, Pedram ^{[1
,2
]}

机构：

[1] Johns Hopkins Univ, Dept Pathol, Johns Hopkins Med Inst, Baltimore, MD 21231 USA

[2] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21231 USA

来源：

HUMAN PATHOLOGY | 2010年 / 41卷 / 06期

关键词：

Breast; Metastasis; HER-2; Autopsy; BIOPSY SPECIMENS; TRASTUZUMAB; EXPRESSION; METASTASES;

D O I：

10.1016/j.humpath.2009.10.022

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

We report a case of a patient with invasive breast carcinoma that demonstrated HER-2 gene amplification on core biopsy, who relapsed while on adjuvant trastuzumab therapy after her mastectomy and ultimately died 15 months after diagnosis. Surprisingly, analysis of multiple metastases harvested at rapid autopsy demonstrated no evidence of HER-2 gene amplification. Retrospective examination of the carcinoma in the patient's mastectomy specimen revealed only focal HER-2 amplification within the tumor, localized to the region of the prior core biopsy site. This case highlights several important issues in HER-2 testing of breast cancer, including core biopsy-excision specimen discordance, primary-metastasis discordance, and potential selection for unamplified portions of a heterogeneously amplified tumors by trastuzumab. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：914 / 917

页数：4

共 15 条

[1]

BRUNELLI M, 2009, AM J CLIN PATHOL, V678, P131

[2] Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study [J].